Tools
Stock profile

Sionna Therapeutics, Inc. (SION)

SION · Latest close $2.97 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$2.97
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
3
vs previous quarter

Sionna Therapeutics, Inc. (SION) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $21.8M sold). Latest close $2.97 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 17, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-21.8M
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RA Capital Management · OrbiMed Advisors · Perceptive Advisors — 6 tracked funds hold SION. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 2 sales ($21.8M). Insider trading

Often held alongside

AVALYN PHARMA INC (AVLN) · BRIGHT MINDS BIOSCIENCES INC (DRUG) · MINERALYS THERAPEUTICS INC (MLYS) · MONOPAR THERAPEUTICS INC (MNPR) · PALISADE BIO INC (PALI) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RA Capital Management3.79%9,905,045HELD Q3 filed Nov 16
OrbiMed Advisors2.08%2,555,877TRIMMED (-27.6%) Q3 filed Nov 16
Perceptive Advisors0.60%905,000ADDED (+37.4%) Q3 filed Nov 16
Viking Global Investors0.40%3,195,181HELD Q3 filed Nov 16
Deerfield Management0.31%680,916TRIMMED (-29.8%) Q3 filed Nov 16
Baker Bros. Advisors0.09%400,000HELD Q3 filed Nov 16
Polen Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -92.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

51.041.052025-02-072026-11-18

Closing prices (unadjusted for dividends), last 2 years — 448 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding151 of 8,857 filers
Long-only filers among them147
Change vs 2026 Q1+34 net · 149 entered · 115 exited
Shares reported, all filers48,084,318
Reported value, all filers$2.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Net income · FY2025$-75.3M
Total assets · FY2025$326.0M
Shares outstanding45,212,399
Market cap (at latest close)$134.3M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20263,676,508
Share of shares outstanding8.13%
Days to cover3.74

Shares short at recent settlements — Jul 31, 2026: 4.2M · Aug 14, 2026: 4.2M · Aug 31, 2026: 4.3M · Sep 15, 2026: 4.0M · Sep 30, 2026: 3.8M · Oct 15, 2026: 3.7M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 14K · Aug 31, 2026: 41K · Sep 15, 2026: 338 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 1 insider ($21.8M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 17, 2026RA CAPITAL MANAGEMENT, L.P.Sell3,415,011$6.32$21.6MSEC filing
Sep 17, 2026RA CAPITAL MANAGEMENT, L.P.Sell33,800$7.46$252.1KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 17, 2026RA Capital Healthcare Fund, L.P.Director, 10% Stockholder3,448,811$21.8MSep 17, 2026SEC filing
Jul 6, 2026JENNIFER FITZPATRICKOfficer10,250$450.9KJul 6, 2026SEC filing
Jun 1, 2026OrbiMed Private Investments VIII, LPShareholder210,876$9.0MMay 29, 2026SEC filing
May 29, 2026OrbiMed Private Investments VIII, LPShareholder1,082,480$46.3MMay 29, 2026SEC filing
Mar 5, 2026JENNIFER FITZPATRICKOfficer10,250$354.3KMar 5, 2026SEC filing
Jan 22, 2026Rise Fund Sling, L.P.Stockholder195,667$8.2MJan 22, 2026SEC filing
Jan 22, 2026Rise Fund Sling II, L.P.Stockholder54,333$2.3MJan 22, 2026SEC filing
Dec 5, 2025JENNIFER R FITZPATRICKOfficer10,250$419.0KDec 5, 2025SEC filing
Nov 24, 2025OrbiMed Private Investments VIII, LPShareholder1,047,770$46.5MNov 24, 2025SEC filing
Nov 21, 2025RA Capital Healthcare Fund LPDirector, 10% Stockholder1,210$52.8KNov 21, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Sep 21, 2026SCHEDULE 13D/A-49.0% (close Sep 22, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Sep 22, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Sep 21, 2026RA Capital Management, L.P.SC 13D/A6,476,19314.3%Sep 17, 2026SEC filing
May 15, 2026VIKING GLOBAL INVESTORS LPSC 13G/A3,195,1817.1%Mar 31, 2026SEC filing
May 12, 2026Qatar Investment AuthoritySC 13G/A2,020,2584.5%Mar 31, 2026SEC filing
Apr 20, 2026ORBIMED ADVISORS LLCSC 13D/A2,967,7226.6%Apr 15, 2026SEC filing
Nov 7, 2025RA Capital Management, L.P.SC 13D/A10,071,71222.6%Nov 5, 2025SEC filing
Oct 31, 2025SC 13G/A———SEC filing
Oct 20, 2025Atlas Venture Fund XI, L.P.SC 13D/A2,382,4955.4%Oct 16, 2025SEC filing
Jul 30, 2025JPMORGAN CHASE & CO.SC 13G2,221,1885.0%Jun 30, 2025SEC filing
Jun 16, 2025Qatar Investment AuthoritySC 13G2,209,7755.0%Jun 11, 2025SEC filing
Feb 18, 2025TPG GP A, LLCSC 13D6,684,96215.2%Feb 10, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Financial Screens

· Net-Net (NCAV) — Market cap below net current asset value

Red Flags

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· Net-Net (NCAV) — NCAV: $222.3M · Market cap: $159.8M · NCAV / market cap: 1.39

· Excess Accruals (Sloan) — Accruals ratio: 33.7% · Net income: $-75.3M · Operating cash flow: $-66.3M · Investing cash flow: $-118.7M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q1, ranked #8 of 50.

Also held by the tracked funds that hold SION — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · BRIGHT MINDS BIOSCIENCES INC (DRUG) · MINERALYS THERAPEUTICS INC (MLYS) · MONOPAR THERAPEUTICS INC (MNPR) · PALISADE BIO INC (PALI) · PARABILIS MEDICINES INC (PBLS) · Pharvaris N.V. (PHVS) · RAPPORT THERAPEUTICS INC (RAPP).

Recent 8-K filings

FiledItemsSource
Nov 10, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Sep 14, 20262.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Aug 10, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on SION

One email a week: the week’s new filings and research. Subscribe free

← SIMO  ·  SIRI →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.